← Aveo Pharmaceuticals, Inc. (AVEO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Aveo Pharmaceuticals, Inc. (AVEO)
Healthcare · market cap —
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-01 (est.)
Phase 2
Pipeline
8
programs
Upcoming events
2
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-11-01 (est.)Phase 2 · Tivozanibimp 7/10
- 2027-08-15 (est.)Phase 3 · Ficlatuzumabimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| tivozanib (AV-951) | Phase 3 | Advanced Renal Cell Carcinoma |
| Ficlatuzumab | Phase 3 | Metastatic Head-and-neck Squamous-cell Carcinoma |
| Tivozanib | Phase 3 | Renal Cell Carcinoma |
| Tivozanib hydrochloride | Phase 3 | Carcinoma, Renal Cell |
| mFOLFOX6 | Phase 2 | Colorectal Cancer |
| Tivozanib (1mg) | Phase 2 | Advanced Adult Hepatocellular Carcinoma |
| AV-299 + gefitinib | Phase 2 | Carcinoma, Non-Small Cell-Lung |
| Samalizumab (BAML-16-001-S1) | Phase 3 | Previously Untreated Relapsed Refractory Acute Myeloid Leukemia |
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for AVEO (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 8 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.